Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Saskatchewan

$27,000.00

Investigating the Effects of Lipid Utilization in Hypercholesterolemia Models of Sepsis

EF 2025-26

Résumé
Sepsis is a life-threatening condition where the body’s reaction to an infection is out of control. While fighting germs, our immune system also causes organ damage and a dangerous drop in blood pressure. Currently, sepsis is the leading cause of death in intensive care units. Treatments for sepsis focus on fighting the infection and stabilizing blood pressure. However, many patients still experience long-term organ damage and complications. Recently, studies showed that lipids such as triglycerides in our body play an important role in sepsis by providing energy to vital organs. This leads us to wonder whether medicines that change how our body handles lipids could improve outcomes in sepsis. Evinacumab is a medicine under investigation to treat patients with familial hypercholesterolemia, a genetic condition that has a high risk of heart disease. Evinacumab works in part by accelerating the metabolism of circulating triglyceride. This raises an exciting question: can Evinacumab accelerate the metabolism of triglyceride in sepsis to improve health outcomes? To explore this, we will investigate the effect of Evinacumab compared to vehicle control on both wild-type mice as well as a mouse model of familial hypercholesterolemia with sepsis. Compared to vehicle, we anticipate Evinacumab will improve health outcomes in mice with sepsis. Moreover, we anticipate Evinacumab will accelerate triglyceride metabolism in mice with familial hypercholesterolemia more than in wild-type mice, and so we also anticipate that mice with familial hypercholesterolemia will respond to Evinacumab even better than wild-type mice. Our study may reveal that Evinacumab could possibly be repurposed as a new therapy to treat sepsis, offering hope for better outcomes for this deadly condition.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Emplacement
Saskatchewan, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
572564
Name
Su Shennan
Region
Saskatchewan
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the Effects of Lipid Utilization in Hypercholesterolemia Models of Sepsis
Programtype2
Studentship Programs
Orgnameinp2
University of Saskatchewan
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Immunometabolism; Lipid Metabolism; Lipoproteins; Sepsis; Stress Biology
Abstract
Sepsis is a life-threatening condition where the body’s reaction to an infection is out of control. While fighting germs, our immune system also causes organ damage and a dangerous drop in blood pressure. Currently, sepsis is the leading cause of death in intensive care units. Treatments for sepsis focus on fighting the infection and stabilizing blood pressure. However, many patients still experience long-term organ damage and complications. Recently, studies showed that lipids such as triglycerides in our body play an important role in sepsis by providing energy to vital organs. This leads us to wonder whether medicines that change how our body handles lipids could improve outcomes in sepsis. Evinacumab is a medicine under investigation to treat patients with familial hypercholesterolemia, a genetic condition that has a high risk of heart disease. Evinacumab works in part by accelerating the metabolism of circulating triglyceride. This raises an exciting question: can Evinacumab accelerate the metabolism of triglyceride in sepsis to improve health outcomes? To explore this, we will investigate the effect of Evinacumab compared to vehicle control on both wild-type mice as well as a mouse model of familial hypercholesterolemia with sepsis. Compared to vehicle, we anticipate Evinacumab will improve health outcomes in mice with sepsis. Moreover, we anticipate Evinacumab will accelerate triglyceride metabolism in mice with familial hypercholesterolemia more than in wild-type mice, and so we also anticipate that mice with familial hypercholesterolemia will respond to Evinacumab even better than wild-type mice. Our study may reveal that Evinacumab could possibly be repurposed as a new therapy to treat sepsis, offering hope for better outcomes for this deadly condition.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Su, Shennan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~